MedTech Europe responds to the EC Call for evidence on the Life Sciences Strategy

MedTech Europe, the European association of medical technology manufacturers, endorses the Commission’s commitment to present a holistic Life Sciences Strategy.

As medical technology’s global competitiveness gap is widening and innovation dropping, designing the Strategy as a comprehensive, cross-sectoral and forward-looking umbrella strategy for European life sciences is without alternative. Medical technologies are an essential part of the life sciences sector and critical for the world-class performance and future resilience of European health systems as patients and healthcare professionals rely on medical technologies in each phase of care pathway, from prevention and detection to therapy and follow-up.

We urge policymakers to place the medical technology sector as an integral part of the EU Life Sciences Strategy and use the upcoming Strategy as an opportunity to reinstall Europe’s attractiveness for medical technology innovation. MedTech Europe welcomes the broadening of the scope, from research-and-innovation-only, and urges policymakers to seize the opportunity of the Strategy by taking seven Priority Actions, ranging from the adoption of a structural reform of the medical technology sector’s regulatory system, better alignment and simplification of regulatory requirements across different policy domains, to allocating strategic investments to build a more efficient, sustainable, and resilient healthcare infrastructure.

Read MedTech Europe’s response below.